How has been the historical performance of Piramal Pharma?

Answer:The historical performance of Piramal Pharma shows a mixed trend over the past few years, with significant fluctuations in key financial metrics.

Breakdown:
Piramal Pharma's net sales have shown a consistent upward trajectory, increasing from 6,559.10 Cr in Mar'22 to 9,151.18 Cr in Mar'25. Total operating income followed a similar pattern, rising from 6,559.10 Cr in Mar'22 to 9,151.18 Cr in Mar'25. However, the total expenditure also increased, from 5,609.44 Cr in Mar'22 to 7,706.35 Cr in Mar'25, leading to an operating profit (PBDIT) growth from 949.66 Cr in Mar'22 to 1,579.64 Cr in Mar'25. Despite this growth, profit before tax fluctuated, peaking at 425.95 Cr in Mar'22 but dropping to 341.71 Cr in Mar'25. The profit after tax saw a significant decline in Mar'23 to -240.79 Cr, but rebounded to 18.20 Cr in Mar'25. The consolidated net profit also reflected this volatility, moving from 375.96 Cr in Mar'22 to 91.13 Cr in Mar'25. On the balance sheet, total assets increased from 12,499.77 Cr in Mar'22 to 15,284.46 Cr in Mar'25, while total liabilities rose from 12,499.77 Cr to 15,284.46 Cr over the same period. Cash flow from operating activities improved from 483.00 Cr in Mar'23 to 892.00 Cr in Mar'25, although the net cash outflow was recorded at -36.00 Cr in Mar'25. Overall, while Piramal Pharma has shown growth in sales and operating profit, it has faced challenges in maintaining profitability and managing cash flow effectively.